Reshaping the Clinical Trial Model
A Call for Integration, Innovation, and Data-Driven Design
Anna Hayes, Senior Director, Data Management, Veramed
This article challenges the traditional clinical trial model, advocating for integrated teams, early data expert involvement, and real-time data systems. It explores how automation, hybrid roles, and patient-centric recruitment can streamline trials, enhance data quality, and accelerate outcomes- ultimately reshaping clinical research into a more efficient, collaborative, and future-ready process.
If we were to reimagine how we conduct clinical trials today, would we use the same methods we’ve relied on for decades? I would argue—absolutely not. The traditional model, while foundational, is no longer fit for purpose in a world where technology, data, and patient expectations are evolving rapidly. To truly modernise clinical research, we must rethink not only the tools we use but also the structure of our teams, the timing of our decisions, and the way we collaborate across functions.
At the heart of this transformation is a simple but powerful principle: we need the right people at the right time. This means involving experts early, particularly those in data management, statistical programming, and analytics, so that trial design is informed by how data will be collected, processed, and analysed. Efficiency and effectiveness are not mutually exclusive; they can coexist when we plan smarter and collaborate better.
Designing Trials with Data in Mind
Let’s start with the planning and startup phase. This is where foundational decisions are made- decisions that shape the trajectory of the entire study. Too often, data experts are brought in after the protocol is finalised, forced to work around design choices that complicate data flow and analysis. This reactive model leads to inefficiencies, delays, and missed opportunities for optimisation.
Instead, imagine a model where data collection and statistical analysis experts are embedded in protocol development from day one. Their insights can ensure that endpoints are measurable, data flows are logical, and analysis plans are feasible. For example, a statistician might flag that a proposed endpoint lacks sensitivity or that a data manager could suggest a more streamlined way to capture patient-reported outcomes using mobile technology.
We already have the technology to support this. For instance, it’s now possible to read in a schedule of events and automatically generate a first-draft database, complete with associated metadata. Safety outputs, which are largely standardised, can be automated directly from data collection. This frees up time and resources to focus on study-specific efficacy data—where customisation and expert input are truly needed.
Moreover, early involvement of data experts can help avoid common pitfalls such as protocol amendments due to unanticipated data issues. These amendments are costly, time-consuming, and often preventable. By designing with data in mind, we can build trials that are not only scientifically sound but also operationally efficient.
Breaking Down Silos: A New Functional Model
To reshape clinical trials, we must also rethink our organisational structures. The traditional siloed model—where clinical operations, data management, biostatistics, and monitoring operate in isolation—is no longer sustainable. These silos hinder communication, delay decision-making, and obscure accountability.
Instead, we should be combining functions and fostering hybrid roles that reflect the interconnected nature of modern trials. Take clinical monitoring and data management, for example. These two functions are deeply intertwined, yet they often operate separately. A hybrid model could bring them together into a data surveillance team—a group that uses real-time data as the source of truth to make informed decisions and take proactive actions.
This team would not only monitor site performance but also track data quality, identify trends, and flag potential issues before they escalate. For instance, if a site consistently underreports adverse events or shows irregular visit patterns, the surveillance team can intervene early, preventing protocol deviations and safeguarding data integrity.
Hybrid roles also foster a culture of shared ownership. When team members understand both the clinical and data perspectives, they are better equipped to make holistic decisions. This reduces handoffs, accelerates timelines, and enhances trial oversight.
Visualising Data for Action
Data visualisation is another area ripe for transformation. When done well, visualisations add meaning, context, and clarity to raw data. They allow teams to see the data as it will be presented in statistical outputs, making it easier to spot anomalies, gaps, or inconsistencies early on.
Imagine dashboards that flow seamlessly from operational metrics to statistical summaries. These tools would empower teams to take meaningful actions, whether it’s adjusting recruitment strategies, refining data collection methods, adjusting risk and/or modifying monitoring efforts. The goal is not just to see the data but to understand it and act on it.
For example, a dashboard might show that a particular site is enrolling patients rapidly but has a high rate of missing data. This insight allows the team to investigate and address the issue before it affects the overall study quality. Similarly, visualisations of adverse event trends can help identify safety signals early, enabling timely risk mitigation.
Visualisation also supports cross-functional communication. When everyone—from clinical leads to statisticians to project managers—can see and interpret the same data, alignment improves. Decisions become faster, more transparent, and more data-driven.
Optimising Data Acquisition and Flow
Despite years of effort, the industry still struggles with data standards and interoperability. Standards are not new, but their implementation remains inconsistent. We need to move beyond manual processes and embrace automation that facilitates real-time data access. This means leveraging APIs, eliminating duplicate data entry, and reducing the burden on sites and patients.
The concept of the clinical database also needs to evolve. It’s no longer just the electronic Case Report Form (eCRF). Today’s database should be a system—a dynamic platform that integrates clinical data with external sources, transforming raw inputs into actionable insights. This system should be accessible to all stakeholders, serving as a portal for reviewing dashboards, visualisations, and key metrics.
When everyone works within the same system, communication improves, silos break down, and decisions become data-driven. For example, integrating lab data, wearable device outputs, and patient-reported outcomes into a single platform allows for a more comprehensive view of patient health and trial progress.
Furthermore, real-time data access enables adaptive trial designs. If interim data suggests a need to modify the protocol or adjust dosing, teams can respond quickly, improving both safety and efficacy outcomes.
Empowering Patients Through Access
Patient recruitment is another area where innovation is urgently needed. Instead of relying solely on-site outreach or physician referrals, we should be giving patients direct access to information about clinical trials. Imagine a platform where individuals can search for trials relevant to their condition, location, or treatment history, and then enroll directly or discuss options with their healthcare provider.
This approach empowers patients, increases diversity and improves recruitment efficiency. It turns clinical trials into a treatment option, not just a research endeavour. Patients are no longer passive participants; they become informed collaborators in their own care journey.
Moreover, patient-centric tools can improve retention. When patients understand the purpose of the trial, see how their data is used, and feel supported throughout the process, they are more likely to stay engaged. Features like mobile apps for visit reminders, symptom tracking, and direct communication with study staff can enhance the patient experience and reduce dropout rates.
Patient access also supports diversity in clinical trials. By removing geographic and informational barriers, we can reach underrepresented populations and ensure that study results are generalisable across demographics.
Bridging the Gap Between Commercial and R&D
Finally, we must address the disconnect between commercial teams and research and development. I have a close family member working in pharmaceutical sales, and it’s striking how little visibility they have into ongoing or upcoming clinical trials, especially in therapeutic areas they specialize in. This lack of integration represents a missed opportunity.
Sales teams are deeply embedded in the healthcare ecosystem. They understand physician needs, patient concerns, and market dynamics. If they were more connected to R&D, they could help identify trial opportunities, support recruitment, and even inform protocol design based on real-world insights.
For example, a sales representative might hear from physicians that a particular patient population is underserved or that a competitor’s trial is gaining traction. This intelligence could be invaluable for designing trials that meet actual clinical needs and for positioning studies as attractive options for both sites and patients.
Bridging this gap could unlock new synergies and accelerate innovation. It would also foster a more unified organisational culture, where commercial and scientific goals align to serve patients better.
A Vision for the Future
So, what would a reimagined clinical trial look like?
- Integrated teams where data experts, statisticians, and clinical leads collaborate from the start.
- Hybrid roles that combine monitoring and data management into proactive surveillance functions.
- Automated systems that generate databases, safety outputs, and visualisations from protocol inputs.
- Real-time data access through APIs and interoperable platforms.
- Patient-centric recruitment tools that empower individuals to explore trial options.
- Cross-functional collaboration between commercial and R&D teams.
This vision is not just aspirational—it’s achievable. The tools exist. The talent exists. What’s needed is a shift in mindset and a willingness to challenge the status quo.
Clinical trials are complex, but complexity should not be a barrier to innovation. By rethinking how we design, conduct, and manage trials, we can create a model that is not only more efficient but also more inclusive, transparent, and impactful.
Let’s stop asking whether we can change and start asking how soon we can begin.
Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.
